MX2022014586A - Métodos y composiciones para tratar la fuga vascular. - Google Patents
Métodos y composiciones para tratar la fuga vascular.Info
- Publication number
- MX2022014586A MX2022014586A MX2022014586A MX2022014586A MX2022014586A MX 2022014586 A MX2022014586 A MX 2022014586A MX 2022014586 A MX2022014586 A MX 2022014586A MX 2022014586 A MX2022014586 A MX 2022014586A MX 2022014586 A MX2022014586 A MX 2022014586A
- Authority
- MX
- Mexico
- Prior art keywords
- syndecan
- compositions
- methods
- respiratory distress
- distress syndrome
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002792 vascular Effects 0.000 title 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 3
- 102000003711 Syndecan-2 Human genes 0.000 abstract 3
- 108090000054 Syndecan-2 Proteins 0.000 abstract 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 3
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proveen anticuerpos anti-sindecano-2 y composiciones que comprenden dicho anticuerpo y métodos útiles para tratar el síndrome de dificultad respiratoria aguda, incluyendo el síndrome de dificultad respiratoria aguda inducido por la enfermedad de coronavirus 2019, en un sujeto en necesidad del mismo; el método comprende administrar al sujeto una cantidad efectiva para tratar el síndrome de dificultad respiratoria aguda de un agente disruptivo del sindecano-2; los agentes disruptivos del sindecano-2 pueden incluir por lo menos uno de los anticuerpos anti-sindecano-2 y/o por lo menos un péptido disruptivo del sindecano-2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063029062P | 2020-05-22 | 2020-05-22 | |
PCT/US2021/033759 WO2021237159A1 (en) | 2020-05-22 | 2021-05-21 | Methods and compositions to treat vascular leak |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022014586A true MX2022014586A (es) | 2023-05-17 |
Family
ID=78707631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022014586A MX2022014586A (es) | 2020-05-22 | 2021-05-21 | Métodos y composiciones para tratar la fuga vascular. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230203187A1 (es) |
EP (1) | EP4153207A4 (es) |
JP (1) | JP2023537452A (es) |
KR (1) | KR20230024289A (es) |
CN (1) | CN116437953A (es) |
AU (1) | AU2021273980A1 (es) |
CA (1) | CA3179428A1 (es) |
MX (1) | MX2022014586A (es) |
WO (1) | WO2021237159A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023215787A1 (en) * | 2022-05-04 | 2023-11-09 | Vst Bio Corporation | Compositions and methods for selective regulation of vascular permeability |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150143625A (ko) * | 2013-04-16 | 2015-12-23 | 오르브센 테라퓨틱스 리미티드 | 신데칸 2의 의학적 용도 |
WO2016154019A1 (en) * | 2015-03-20 | 2016-09-29 | Orbsen Therapeutics Limited | Modulators of syndecan-2 and uses thereof |
US10358497B2 (en) * | 2015-09-29 | 2019-07-23 | Amgen Inc. | Methods of treating cardiovascular disease with an ASGR inhibitor |
US20210113654A1 (en) * | 2018-05-31 | 2021-04-22 | Yale University | Methods and Compositions to Alleviate Vascular Permeability |
-
2021
- 2021-05-21 CA CA3179428A patent/CA3179428A1/en active Pending
- 2021-05-21 MX MX2022014586A patent/MX2022014586A/es unknown
- 2021-05-21 KR KR1020227044301A patent/KR20230024289A/ko active Search and Examination
- 2021-05-21 US US17/999,639 patent/US20230203187A1/en active Pending
- 2021-05-21 CN CN202180060022.5A patent/CN116437953A/zh active Pending
- 2021-05-21 JP JP2022571118A patent/JP2023537452A/ja active Pending
- 2021-05-21 AU AU2021273980A patent/AU2021273980A1/en active Pending
- 2021-05-21 WO PCT/US2021/033759 patent/WO2021237159A1/en active Application Filing
- 2021-05-21 EP EP21809222.9A patent/EP4153207A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230203187A1 (en) | 2023-06-29 |
AU2021273980A1 (en) | 2023-01-19 |
JP2023537452A (ja) | 2023-09-01 |
KR20230024289A (ko) | 2023-02-20 |
CN116437953A (zh) | 2023-07-14 |
EP4153207A1 (en) | 2023-03-29 |
EP4153207A4 (en) | 2024-06-12 |
CA3179428A1 (en) | 2021-11-25 |
WO2021237159A1 (en) | 2021-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022019085A2 (pt) | Uso de agentes para tratamento de condições respiratórias | |
MX2020013557A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. | |
MX2010006519A (es) | Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina. | |
BR0209147A (pt) | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais | |
MX2007003795A (es) | Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades. | |
NO20070702L (no) | Kombinasjonsbehandling for ikke-hematologisk malignitet ved anvendelse av anti-OGF-1R antistoff | |
MX2022006533A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo. | |
NZ744233A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
MX2021002349A (es) | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. | |
ATE287267T1 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
WO2008079270A3 (en) | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis | |
CR20230128A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos | |
MX2022014332A (es) | Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo. | |
UY31417A1 (es) | Una composicion farmacéutica y un proceso para dicha composicion farmacéutica | |
MX2022014586A (es) | Métodos y composiciones para tratar la fuga vascular. | |
JOP20220218A1 (ar) | طريقة لعلاج الحالات المصاحبة لكوفيد 19 | |
MX2023015070A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo. | |
DE60143078D1 (de) | Pax2 zur behandlung von nierenkrankheiten | |
WO2021056025A3 (en) | Anti-epha10 antibodies and methods of use thereof | |
MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
MX2021004603A (es) | Dosificacion. | |
WO2019232203A3 (en) | Methods and compositions to alleviate vascular permeability | |
WO2023019095A3 (en) | Momelotinib combination therapy | |
MX2023009971A (es) | Composicion farmaceutica que contiene anticuerpo anti-tslp. | |
MX2022015959A (es) | Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. |